These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31218961)

  • 1. Research Progress of Axl Inhibitors.
    Sun ZG; Liu JH; Zhang JM; Qian Y
    Curr Top Med Chem; 2019; 19(15):1338-1349. PubMed ID: 31218961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
    Zhu C; Wei Y; Wei X
    Mol Cancer; 2019 Nov; 18(1):153. PubMed ID: 31684958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
    Corno C; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
    Curr Med Chem; 2016; 23(15):1496-512. PubMed ID: 27048336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axl inhibitors as novel cancer therapeutic agents.
    Shen Y; Chen X; He J; Liao D; Zu X
    Life Sci; 2018 Apr; 198():99-111. PubMed ID: 29496493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerating AXL targeting for TNBC therapy.
    Khera L; Lev S
    Int J Biochem Cell Biol; 2021 Oct; 139():106057. PubMed ID: 34403827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AXL kinase as a novel target for cancer therapy.
    Wu X; Liu X; Koul S; Lee CY; Zhang Z; Halmos B
    Oncotarget; 2014 Oct; 5(20):9546-63. PubMed ID: 25337673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
    Inoue S; Yamane Y; Tsukamoto S; Murai N; Azuma H; Nagao S; Nishibata K; Fukushima S; Ichikawa K; Nakagawa T; Hata Sugi N; Ito D; Kato Y; Goto A; Kakiuchi D; Ueno T; Matsui J; Matsushima T
    Bioorg Med Chem Lett; 2021 Sep; 48():128247. PubMed ID: 34271070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent discovery and development of AXL inhibitors as antitumor agents.
    Liu Z; Chen L; Zhang J; Yang J; Xiao X; Shan L; Mao W
    Eur J Med Chem; 2024 Jun; 272():116475. PubMed ID: 38714043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bemcentinib and Gilteritinib Inhibit Cell Growth and Impair the Endo-Lysosomal and Autophagy Systems in an AXL-Independent Manner.
    Zdżalik-Bielecka D; Kozik K; Poświata A; Jastrzębski K; Jakubik M; Miączyńska M
    Mol Cancer Res; 2022 Mar; 20(3):446-455. PubMed ID: 34782372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
    Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
    Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors.
    Linger RM; Keating AK; Earp HS; Graham DK
    Expert Opin Ther Targets; 2010 Oct; 14(10):1073-90. PubMed ID: 20809868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.
    Tanaka M; Siemann DW
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
    Kimani SG; Kumar S; Bansal N; Singh K; Kholodovych V; Comollo T; Peng Y; Kotenko SV; Sarafianos SG; Bertino JR; Welsh WJ; Birge RB
    Sci Rep; 2017 Mar; 7():43908. PubMed ID: 28272423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor.
    Yokoyama Y; Lew ED; Seelige R; Tindall EA; Walsh C; Fagan PC; Lee JY; Nevarez R; Oh J; Tucker KD; Chen M; Diliberto A; Vaaler H; Smith KM; Albert A; Li G; Bui JD
    Cancer Res; 2019 Apr; 79(8):1996-2008. PubMed ID: 30723115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Axl and Mer kinases in cancer.
    Verma A; Warner SL; Vankayalapati H; Bearss DJ; Sharma S
    Mol Cancer Ther; 2011 Oct; 10(10):1763-73. PubMed ID: 21933973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.
    Myers KV; Amend SR; Pienta KJ
    Mol Cancer; 2019 May; 18(1):94. PubMed ID: 31088471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.
    Ng PS; Foo K; Sim S; Wang G; Huang C; Tan LH; Poulsen A; Liu B; Tee DHY; Ahmad NHB; Wang S; Ke Z; Lee MA; Kwek ZP; Joy J; Anantharajan J; Baburajendran N; Pendharkar V; Manoharan V; Vuddagiri S; Sangthongpitag K; Hill J; Keller TH; Hung AW
    Bioorg Med Chem; 2021 Nov; 49():116437. PubMed ID: 34600239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-phosphorylation, signaling and proliferative functions of the Tyro3 and Axl receptors in Rat2 cells.
    Brown JE; Krodel M; Pazos M; Lai C; Prieto AL
    PLoS One; 2012; 7(5):e36800. PubMed ID: 22606290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.
    Schoumacher M; Burbridge M
    Curr Oncol Rep; 2017 Mar; 19(3):19. PubMed ID: 28251492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate.
    Keung W; Boloor A; Brown J; Kiryanov A; Gangloff A; Lawson JD; Skene R; Hoffman I; Atienza J; Kahana J; De Jong R; Farrell P; Balakrishna D; Halkowycz P
    Bioorg Med Chem Lett; 2017 Feb; 27(4):1099-1104. PubMed ID: 28082036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.